X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI –Report highlights increasing prevalence for Alzheimer’s disease

By Andrew Powaleny  |    December 11, 2017
The number of Americans affected by Alzheimer’s disease (AD) continues to rise according to a new report.1 Researchers found that approximately 6.08 million Americans had Alzheimer’s or mild...   Read More

New surveys find payers and providers want more data from biopharmaceutical companies

By Joe Vandigo  |    December 6, 2017
Both payers and providers are interested in additional information from biopharmaceutical companies about prescription medicines – including information about pipeline medicines and unapproved...   Read More

World AIDS Day 2017: Scientific breakthroughs paving the way for an AIDS-free generation

By Andrew Powaleny  |    December 1, 2017
Today marks World AIDS Day, a moment to reflect on the significant advances made in the treatment and prevention of HIV, the virus which causes AIDS. The incredible scientific progress...   Read More

EFPIA-PhRMA Principles successfully enable responsible clinical trial data sharing

By Olivia Shopshear  |    November 29, 2017
Stakeholders are gathering in London this week for a workshop entitled Data Anonymization – a Key Enabler for Clinical Data Sharing. The workshop, jointly organized by the European Medicines...   Read More

Guest Post: Film chronicles clinical trials ‘paying it forward’

By Guest Contributor  |    November 28, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Supporting opportunities for enhanced competition in the marketplace

By Andrew Powaleny  |    November 22, 2017
Promoting competition is an important focus for the biopharmaceutical industry. Since 1984, the Hatch-Waxman Act has fostered robust competition through the timely entry of generic medicines into...   Read More

New report shows better diabetes management saves money and improves patient outcomes

By Carolyn Ha  |    November 21, 2017
A recent IHS Markit report, “The Clinical and Economic Benefits of Better Treatment of Adult Medicaid Beneficiaries with Diabetes,” simulated savings in the Medicaid program as a result of better...   Read More

Medicare Monday: PhRMA’s comments on new direction for CMMI

By Nicole Longo  |    November 20, 2017
Today, PhRMA submitted its comments in response to the Centers for Medicare & Medicaid Services (CMS) request for information on the future of the Center for Medicare and Medicaid Innovation...   Read More

Medicare Monday: Same bad ideas continue to threaten Part D and beneficiary access to medicines

By Nicole Longo  |    November 13, 2017
Perhaps the biggest fact that is often overlooked about Part D is that there is already significant price negotiation in the program. Thanks to Part D’s competitive structure, large purchasers...   Read More

Video: What is a results-based contract?

By Katie Koziara  |    November 13, 2017
New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates